---
title: "Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293721273.md"
description: "AstraZeneca faces a rare challenge to its track record as shares slide following a clinical trial failure. CEO Pascal Soriot, who has overseen a quadrupling of share price over 14 years, now confronts this setback against the backdrop of the company's historically strong performance and diverse drug portfolio."
datetime: "2026-07-24T08:06:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293721273.md)
  - [en](https://longbridge.com/en/news/293721273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293721273.md)
generator: "portal-rs"
---

# Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. AstraZeneca's huge diversity and number of drugs on the market and success in clinical trials in different therapeutic areas set it

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value](https://longbridge.com/en/news/296923180.md)
- [Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT](https://longbridge.com/en/news/296872454.md)
- [BREAKINGVIEWS-AstraZeneca's blocked M&A signals tough CEO finale](https://longbridge.com/en/news/296766497.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**